Sector News

Bristol-Myers’ rumored activists ‘haven’t made a decision’ on the company yet: Starboard CEO

February 7, 2019
Life sciences

Activist hedge fund Starboard Value is “certainly interested in the story at Bristol-Myers,” according to its leader. But that doesn’t mean it’s getting involved.

As Starboard’s CEO, Jeff Smith, told CNBC on Tuesday, Bristol-Myers Squibb “might fit” the profile of a company on which Starboard thinks it can have a positive impact. But “it might not fit that profile. We haven’t made that decision,” he said.

The comments come after a Monday Bloomberg report that the proxy brawler had already picked up a stake in BMS. In response, analysts surmised that Starboard may be looking to thwart the New Jersey drugmaker’s $74 billion deal agreement for Celgene, perhaps by getting another pharma giant to buy Bristol.

Still, they expressed doubts around that idea—in part because the list of pharma players who could actually swallow BMS is short, not to mention unwilling.

AbbVie, Pfizer and Novartis could potentially pull it off, “but all these would require a lot of synergies to be accretive,” Bloomberg Intelligence’s Sam Fazeli told the news service, with Credit Suisse’s Vamil Divan adding in a note to clients that, “We would be surprised if activists are successful in pushing for a larger change.”

As CNBC’s David Faber noted, Starboard also currently has its hands full meddling in other companies, such as pizza chain Papa John’s.

Starboard has “so many different things going on, to take a significant stake where they would actually argue against a deal—who knows,” he said Monday. He also pointed to last year’s deal pact between United Technologies Corporation and Rockwell Collins, reminding viewers of then-rumors that Starboard could pick up a stake and argue against that deal. “Nothing ever came of it,” he said.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach